Profound Medical Corp. introduced its TULSA‑AI Volume Reduction module, an AI‑driven, MRI‑guided system that expands the existing TULSA‑PRO platform to treat benign prostatic hyperplasia (BPH). The new module allows physicians to stack multiple prostate cases in a single day using the same TULSA‑PRO hardware, clinical support staff, and reimbursement codes, thereby increasing system utilization and broadening the company’s addressable market to an estimated 600,000 BPH patients annually.
Continue reading for full analysis...
Profound Medical Corp. marked a significant milestone on November 18, 2025, when Dr. Y. Mark Hong at The Hong Center Scottsdale completed the company’s 200th independent TULSA procedure. The procedure was performed entirely by a urologist, without radiologist involvement, demonstrating the feasibility of a urologist‑led workflow on the TULSA‑PRO system.
Continue reading for full analysis...
Profound Medical Corp. reported third‑quarter 2025 revenue of $5.3 million, an 87% increase from $2.8 million a year earlier. The growth was driven by a $4.1 million rise in recurring revenue and a $1.2 million increase in one‑time capital equipment sales, reflecting a growing installed base of its TULSA‑PRO system.
Continue reading for full analysis...